American veterans have been vocal in the discourse regarding medical marijuana. Scientists found that people with Post Traumatic Stress Disorder (PTSD) are deficient in endocannabinoids. They also found that CB1 receptors signal the deactivation of traumatic memories. PTSD is increasingly popping up on states’ lists of qualifying conditions for medical marijuana. In June 2017, Colorado added PTSD to its list making it the ninth and most recent qualifying condition. New York added PTSD to its tightly controlled program this year after pressure from veterans groups made its way to the governor. Those affected by PTSD often suffer from extreme anxiety, drastically impacting their life and ability to interact with others.
On the other hand, marijuana-derived CBD and anything else derived from a cannabis plant was still classified by the DEA as a Schedule I drug (defined as a drug with "no currently accepted medical use and a high potential for abuse") until October 2018. In 2016, the DEA stated that all extracts containing more than one cannabinoid would remain classified as Schedule I. However, the approval of Epidiolex had an influence in changing this, and prescription CBD drugs with a THC content of below 0.1% have now been reclassified as Schedule 5, the lowest rating.
As someone dealing with anxiety — hi pals, isn't this pool getting crowded? — all day, every day, taking CBD oil sounded like something that was at least worth a shot. So, I contacted Charlotte's Web by the Stanley Brothers, a CBD hemp oil company based in Colorado. Their hemp oil had positive reviews, which is good for me and my tattered memories of freshman year. They kindly sent me some of their Everyday Advanced Oil, which they recommend taking 0.6 ml of twice a day. I decide to try it for a week.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
GPR55 antagonism: GPR55 (G-protein-coupled receptor 55) is a receptor expressed predominantly within the caudate nucleus and putamen. It is often referenced as an atypical cannabinoid receptor due to the fact that it is activated by cannabinoids. A study published in 2015 investigated the role of GPR55 function in anxiety. Researchers concluded that GPR55 may modulate anxiety-related behaviors in rats. In the study, it was discovered that GPR55 antagonists lead to increased anxiety. Cannabidiol is thought to act as a GPR55 antagonist which may improve bone health and decrease proliferation of cancer cells – but may not help anxiety.
CBD products that don't contain THC fall outside the scope of the U.S. Drug Enforcement Agency's (DEA) Controlled Substances Act, which means CBD products are legal to sell and consume as long as they don't have THC. That's likely one of the reasons why CBD products, including CBD oil, are becoming more socially acceptable and increasingly popular. In 2016, Forbes reported that CBD products are expected to be a $2.2 billion industry by 2020.
Medical Disclaimer: Statements in any video or written content on this site have not been evaluated by the FDA. If you are pregnant, nursing, taking medications, or have a medical condition, consult your physician before using this product. Representations regarding the efficacy and safety of CBD oil have not been evaluated by the Food and Drug Administration. The FDA only evaluates foods and drugs, not supplements like these products. These products are not intended to diagnose, prevent, treat, or cure any disease. The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any supplement program.
Copyright © thejoyfullotus.com